ZymoGenetics, Inc. is a biopharmaceutical company focused on the discovery and development of protein therapeutics that prevent or treat significant human diseases. The company launched its first product on the U.S. market in 2008 and has a strong pipeline of additional products in development. Warburg Pincus has been a significant investor in ZymoGenetics since 2000. |
||
|
|